Drug intelligence / Profile preview

CBT-002

Development stage: Preclinical
Lead developer: C-BIOMEX
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

CBT-002 is a therapeutic radiopharmaceutical under preclinical development by C-BIOMEX. It acts as an antagonist of somatostatin receptor 2 (SSTR2), a target commonly expressed in neuroendocrine tumors. By antagonizing SSTR2, CBT-002 may inhibit tumor growth or facilitate targeted delivery of radiotherapeutic agents to SSTR2-expressing neoplasms. The drug is being investigated primarily for the treatment of neuroendocrine tumors[1].

Targets

SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on CBT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-002.

Explore the full profile